Antigen delivery systems for veterinary vaccine development. Viral-vector based delivery systems

Vaccine

Volumn 26, Issue 51, 2008, Pages 6508-6528

  Brun, Alejandro ^a   Albina, Emmanuel ^b   Barret, Tom ^c   Chapman, David A G ^c   Czub, Markus ^d   Dixon, Linda K ^c   Keil, Günther M ^f   Klonjkowski, Bernard ^g   Le Potier, Marie Frédérique ^e   Libeau, Geneviève ^b   Ortego, Javier ^a   Richardson, Jennifer ^g   Takamatsu, Haru H ^c  

^a Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria   (Spain)

^b CIRAD   (France)

^c INSTITUTE FOR ANIMAL HEALTH   (United Kingdom)

^d UNIVERSITY OF CALGARY   (Canada)

^e Healthy Pigs Production and Experimentation Section   (France)

^f FEDERAL RESEARCH INSTITUTE FOR ANIMAL HEALTH   (Germany)

^g ECOLE NATIONALE VÉTÉRINAIRE D ALFORT   (France)

Author keywords

Adenovirus vectors; Antigen delivery systems; Baculovirus vectors; Herpesvirus vectors; Modified live virus; Negative strand RNA virus vectors; Positive strand RNA virus vectors; Poxvirus vectors; Veterinary vaccines; Viral vectors

Indexed keywords

ADENOVIRUS VECTOR; BACULOVIRUS VECTOR; BAYPAMUN; D 1701; HERPESVIRUS VECTOR; RABORAL V RG; RETROVIRUS VECTOR; TROVAC; UNCLASSIFIED DRUG; VETERINARY DRUG; VIRUS VECTOR;

ALPHA VIRUS; BUNYAVIRUS; CORONAVIRUS; DRUG DELIVERY SYSTEM; DRUG DESIGN; EPIZOOTIOLOGY; FLAVIVIRUS; IMMUNOMODULATION; MOLECULAR GENETICS; NONHUMAN; PARAMYXOVIRUS; POXVIRUS; PRIORITY JOURNAL; REVIEW; RHABDOVIRUS; VIRAL GENE THERAPY;

ANIMALS; ANTIGENS, VIRAL; DNA VIRUSES; DRUG DELIVERY SYSTEMS; RNA VIRUSES; VACCINES, ATTENUATED; VIRAL VACCINES; VIRUS DISEASES;

EID: 58149191453     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.09.044     Document Type: Review

References (343)

1. Holmgren J., Czerkinsky C., Lycke N., and Svennerholm A.M. Mucosal immunity - implications for vaccine development. Immunobiology 184 February (2-3) (1992) 157-179
2. McGhee J.R., Mestecky J., Dertzbaugh M.T., Eldridge J.H., Hirasawa M., and Kiyono H. The mucosal immune system - from fundamental concepts to vaccine development. Vaccine 10 2 (1992) 75-88
3. Babiuk L.A., LittelvandenHurk S.V., Tikoo S.K., Lewis P.J., and Liang X. Novel viral vaccines for livestock. Vet Immunol Immunopathol 54 November (1-4) (1996) 355-363
4. Monaco F., Cammà C., Serini S., and Savini G. Differentiation between field and vaccine strain of bluetongue virus serotype 16. Vet Microbiol 116 (2004) 45-52
5. Lubroth J., Rweyemamu M.M., Viljoen G., Diallo A., Dungu B., and Amafu W. Veterinary vaccines and their use in developing countries. Revue Scientifique Et Tech-Off Int Des Epizooties 26 April (1) (2007) 179-201
6. Cleaveland S., Kaare M., Knobel D., and Laurenson M.K. Canine vaccination - providing broader benefits for disease control. Vet Microbiol 117 October (1) (2006) 43-50
7. Plowright W., and Ferris R.D. Studies with rinderpest virus in tissue culture. The use of attenuated culture virus as a vaccine for cattle. Res Vet Sci 3 (1962) 172-182
8. Baron M.D., Banyard A.C., Parida S., and Barrett T. The Plowright vaccine strain of Rinderpest virus has attenuating mutations in most genes. J Gen Virol 86 April (Pt 4) (2005) 1093-1101
9. Smithburn K.C. Rift Valley fever; the neurotropic adaptation of the virus and the experimental use of this modified virus as a vaccine. Br J Exp Pathol 30 February (1) (1949) 1-16
10. Swanepoel R., and Coetzer J.A.W. Rift Valley fever. In: Coetzer J.A.W., and Tustin R.C. (Eds). Infectious diseases of livestock. 2nd ed. (2004), Oxford University Press, Cape Town 1037-1070
11. Barnard B.J. Rift Valley fever vaccine - antibody and immune response in cattle to a live and an inactivated vaccine. J S Afr Vet Assoc 50 September (3) (1979) 155-157
12. Hunter P., and Bouloy M. Investigation of C13 Rift Valley fever mutant as a vaccine strain. 5th International Sheep Veterinary Congress. South Africa (2001)
13. Manso Ribeiro J.J., Nunes Petisca J.L., Lopes Frazão F., and Sobral M. Vaccination contre la peste porcine. Bull Off Int des epizooties 60 (1963) 921-937
14. Shi H.Y., Liu X.F., Zhang X.R., Chen S.C., Sun L., and Lu J.H. Generation of an attenuated H5N1 avian influenza virus vaccine with all eight genes from avian viruses. Vaccine 25 October (42) (2007) 7379-7384
15. Risatti G.R., Holinka L.G., Lu Z., Kutish G.F., Tulman E.R., French R.A., et al. Mutation of E1 glycoprotein of classical swine fever virus affects viral virulence in swine. Virology 343 December (1) (2005) 116-127
16. Risatti G.R., Holinka L.G., Carrillo C., Kutish G.F., Lu Z., Tulman E.R., et al. Identification of a novel virulence determinant within the E2 structural glycoprotein of classical swine fever virus. Virology 355 November (1) (2006) 94-101
17. Risatti G.R., Holinka L.G., Fernandez Sainz I., Carrillo C., Kutish G.F., Lu Z., et al. Mutations in the carboxyl terminal region of E2 glycoprotein of classical swine fever virus are responsible for viral attenuation in swine. Virology 364 August (2) (2007) 371-382
18. Risatti G.R., Holinka L.G., Fernandez Sainz I., Carrillo C., Lu Z., and Borca M.V. N-linked glycosylation status of classical swine fever virus strain Brescia E2 glycoprotein influences virulence in swine. J Virol 81 January (2) (2007) 924-933
19. Sainz I.F., Holinka L.G., Lu Z., Risatti G.R., and Borca M.V. Removal of a N-linked glycosylation site of classical swine fever virus strain Brescia Erns glycoprotein affects virulence in swine. Virology 370 January (1) (2008) 122-129
20. Kit S. Genetically engineered vaccines for control of Aujeszky's disease (pseudorabies). Vaccine 8 (1990) 420-424
21. Merchlinsky M., and Moss B. Introduction of foreign DNA into the vaccinia virus genome by in vitro ligation: recombination-independent selectable cloning vectors. Virology 190 September (1) (1992) 522-526
22. Perkus M.E., Piccini A., Lipinskas B.R., and Paoletti E. Recombinant vaccinia virus: immunization against multiple pathogens. Science 229 September (4717) (1985) 981-984
23. Carroll M.W., Overwijk W.W., Surman D.R., Tsung K., Moss B., and Restifo N.P. Construction and characterization of a triple-recombinant vaccinia virus encoding B7-1, interleukin 12, and a model tumor antigen. J Natl Cancer Inst 90 December (24) (1998) 1881-1887
24. Boyle D.B., Anderson M.A., Amos R., Voysey R., and Coupar B.E. Construction of recombinant fowlpox viruses carrying multiple vaccine antigens and immunomodulatory molecules. Biotechniques 37 July (1) (2004) 104-106 8-11
25. Panicali D., and Paoletti E. Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci U S A 79 August (16) (1982) 4927-4931
26. Mackett M., Smith G.L., and Moss B. Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci U S A 79 December (23) (1982) 7415-7419
27. Blancou J., Kieny M.P., Lathe R., Lecocq J.P., Pastoret P.P., Soulebot J.P., et al. Oral vaccination of the fox against rabies using a live recombinant vaccinia virus. Nature 322 July (6077) (1986) 373-375
28. Brochier B., Costy F., and Pastoret P.P. Elimination of fox rabies from Belgium using a recombinant vaccinia-rabies vaccine: an update. Vet Microbiol 46 September (1-3) (1995) 269-279
29. Brochier B., Aubert M.F., Pastoret P.P., Masson E., Schon J., Lombard M., et al. Field use of a vaccinia-rabies recombinant vaccine for the control of sylvatic rabies in Europe and North America. Rev Sci Tech 15 September (3) (1996) 947-970
30. Sutter G., and Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc Natl Acad Sci U S A 89 November (22) (1992) 10847-10851
31. Tartaglia J., Perkus M.E., Taylor J., Norton E.K., Audonnet J.C., Cox W.I., et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology 188 May (1) (1992) 217-232
32. Sutter G., and Staib C. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr Drug Targets Infect Disord 3 (2003) 263-271
33. Kitching R.P., Hammond J.M., and Taylor W.P. A single vaccine for the control of capripox infection in sheep and goats. Res Vet Sci 42 January (1) (1987) 53-60
34. Hunter P., and Wallace D. Lumpy skin disease in southern Africa: a review of the disease and aspects of control. J S Afr Vet Assoc 72 June (2) (2001) 68-71
35. Romero C.H., Barrett T., Chamberlain R.W., Kitching R.P., Fleming M., and Black D.N. Recombinant capripoxvirus expressing the hemagglutinin protein gene of rinderpest virus: protection of cattle against rinderpest and lumpy skin disease viruses. Virology 204 October (1) (1994) 425-429
36. Ngichabe C.K., Wamwayi H.M., Ndungu E.K., Mirangi P.K., Bostock C.J., Black D.N., et al. Long term immunity in African cattle vaccinated with a recombinant capripox-rinderpest virus vaccine. Epidemiol Infect 128 April (2) (2002) 343-349
37. Berhe G., Minet C., Le Goff C., Barrett T., Ngangnou A., Grillet C., et al. Development of a dual recombinant vaccine to protect small ruminants against peste-des-petits-ruminants virus and capripoxvirus infections. J Virol 77 January (2) (2003) 1571-1577
38. Wade-Evans A.M., Romero C.H., Mellor P., Takamatsu H., Anderson J., Thevasagayam J., et al. Expression of the major core structural protein (VP7) of bluetongue virus, by a recombinant capripox virus, provides partial protection of sheep against a virulent heterotypic bluetongue virus challenge. Virology 220 June (1) (1996) 227-231
39. Perrin A., Albina E., Breard E., Sailleau C., Prome S., Grillet C., et al. Recombinant capripoxviruses expressing proteins of bluetongue virus: evaluation of immune responses and protection in small ruminants. Vaccine 25 September (37-38) (2007) 6774-6783
40. Aspden K., van Dijk A.A., Bingham J., Cox D., Passmore J.A., and Williamson A.L. Immunogenicity of a recombinant lumpy skin disease virus (neethling vaccine strain) expressing the rabies virus glycoprotein in cattle. Vaccine 20 June (21-22) (2002) 2693-2701
41. Aspden K., Passmore J.A., Tiedt F., and Williamson A.L. Evaluation of lumpy skin disease virus, a capripoxvirus, as a replication-deficient vaccine vector. J Gen Virol 84 August (Pt 8) (2003) 1985-1996
42. Wallace D.B., Ellis C.E., Espach A., Smith S.J., Greyling R.R., and Viljoen G.J. Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever. Vaccine 24 November (49-50) (2006) 7181-7189
43. Letellier C., Burny A., and Meulemans G. Construction of a pigeonpox virus recombinant: expression of the Newcastle disease virus (NDV) fusion glycoprotein and protection of chickens against NDV challenge. Arch Virol 118 1-2 (1991) 43-56
44. Kerr P.J., and Jackson R.J. Myxoma virus as a vaccine vector for rabbits: antibody levels to influenza virus haemagglutinin presented by a recombinant myxoma virus. Vaccine 13 December (17) (1995) 1722-1726
45. Bertagnoli S., Gelfi J., Le Gall G., Boilletot E., Vautherot J.F., Rasschaert D., et al. Protection against myxomatosis and rabbit viral hemorrhagic disease with recombinant myxoma viruses expressing rabbit hemorrhagic disease virus capsid protein. J Virol 70 August (8) (1996) 5061-5066
46. Torres J.M., Sanchez C., Ramirez M.A., Morales M., Barcena J., Ferrer J., et al. First field trial of a transmissible recombinant vaccine against myxomatosis and rabbit hemorrhagic disease. Vaccine 19 August (31) (2001) 4536-4543
47. van der Leek M.L., Feller J.A., Sorensen G., Isaacson W., Adams C.L., Borde D.J., et al. Evaluation of swinepox virus as a vaccine vector in pigs using an Aujeszky's disease (pseudorabies) virus gene insert coding for glycoproteins gp50 and gp63. Vet Rec 134 January (1) (1994) 13-18
48. Tripathy D.N. Swinepox virus as a vaccine vector for swine pathogens. Adv Vet Med 41 (1999) 463-480
49. Bublot M., Pritchard N., Swayne D.E., Selleck P., Karaca K., Suarez D.L., et al. Development and use of fowlpox vectored vaccines for avian influenza. Ann N Y Acad Sci 1081 October (2006) 193-201
50. Kundig T.M., Kalberer C.P., Hengartner H., and Zinkernagel R.M. Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination. Vaccine 11 11 (1993) 1154-1158
51. Swayne D.E., Beck J.R., and Kinney N. Failure of a recombinant fowl poxvirus vaccine containing an avian influenza hemagglutinin gene to provide consistent protection against influenza in chickens preimmunized with a fowl pox vaccine. Avian Dis 44 January-March (1) (2000) 132-137
52. Viner K.M., Girgis N., Kwak H., and Isaacs S.N. B5-deficient vaccinia virus as a vaccine vector for the expression of a foreign antigen in vaccinia immune animals. Virology 361 May (2) (2007) 356-363
53. Ramirez J.C., Gherardi M.M., Rodriguez D., and Esteban M. Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector. J Virol 74 August (16) (2000) 7651-7655
54. Taylor J., and Paoletti E. Fowlpox virus as a vector in non-avian species. Vaccine 6 December (6) (1988) 466-468
55. Skinner M.A., Laidlaw S.M., Eldaghayes I., Kaiser P., and Cottingham M.G. Fowlpox virus as a recombinant vaccine vector for use in mammals and poultry. Expert Rev Vaccines 4 February (1) (2005) 63-76
56. Zheng M., Jin N., Zhang H., Jin M., Lu H., Ma M., et al. Construction and immunogenicity of a recombinant fowlpox virus containing the capsid and 3C protease coding regions of foot-and-mouth disease virus. J Virol Methods 136 September (1-2) (2006) 230-237
57. Karaca K., Swayne D.E., Grosenbaugh D., Bublot M., Robles A., Spackman E., et al. Immunogenicity of fowlpox virus expressing the avian influenza virus H5 gene (TROVAC AIV-H5) in cats. Clin Diagn Lab Immunol 12 November (11) (2005) 1340-1342
58. Shen G., Jin N., Ma M., Jin K., Zheng M., Zhuang T., et al. Immune responses of pigs inoculated with a recombinant fowlpox virus coexpressing GP5/GP3 of porcine reproductive and respiratory syndrome virus and swine IL-18. Vaccine 25 May (21) (2007) 4193-4202
59. Taylor J., Trimarchi C., Weinberg R., Languet B., Guillemin F., Desmettre P., et al. Efficacy studies on a canarypox-rabies recombinant virus. Vaccine 9 March (3) (1991) 190-193
60. Taylor J., Meignier B., Tartaglia J., Languet B., VanderHoeven J., Franchini G., et al. Biological and immunogenic properties of a canarypox-rabies recombinant. ALVAC-RG (vCP65) in non-avian species. Vaccine 13 April (6) (1995) 539-549
61. Pardo M.C., Bauman J.E., and Mackowiak M. Protection of dogs against canine distemper by vaccination with a canarypox virus recombinant expressing canine distemper virus fusion and hemagglutinin glycoproteins. Am J Vet Res 58 August (8) (1997) 833-836
62. Welter J., Taylor J., Tartaglia J., Paoletti E., and Stephensen C.B. Vaccination against canine distemper virus infection in infant ferrets with and without maternal antibody protection, using recombinant attenuated poxvirus vaccines. J Virol 74 July (14) (2000) 6358-6367
63. Minke J.M., Fischer L., Baudu P., Guigal P.M., Sindle T., Mumford J.A., et al. Use of DNA and recombinant canarypox viral (ALVAC) vectors for equine herpes virus vaccination. Vet Immunol Immunopathol 111 May (1-2) (2006) 47-57
64. Poulet H., Minke J., Pardo M.C., Juillard V., Nordgren B., and Audonnet J.C. Development and registration of recombinant veterinary vaccines. The example of the canarypox vector platform. Vaccine 25 July (30) (2007) 5606-5612
65. Grosenbaugh D.A., Leard T., and Pardo M.C. Protection from challenge following administration of a canarypox virus-vectored recombinant feline leukemia virus vaccine in cats previously vaccinated with a killed virus vaccine. J Am Vet Med Assoc 228 March (5) (2006) 726-727
66. Boone J.D., Balasuriya U.B., Karaca K., Audonnet J.C., Yao J., He L., et al. Recombinant canarypox virus vaccine co-expressing genes encoding the VP2 and VP5 outer capsid proteins of bluetongue virus induces high level protection in sheep. Vaccine 25 January (4) (2007) 672-678
67. Diallo A., Minet C., Berhe G., Le Goff C., Black D.N., Fleming M., et al. Goat immune response to capripox vaccine expressing the hemagglutinin protein of peste des petits ruminants. Ann N Y Acad Sci 969 October (2002) 88-91
68. Rziha H.J., Henkel M., Cottone R., Meyer M., Dehio C., and Büttner M. Parapoxviruses: potential alternative vectors for directing the immune response in permissive and non-permissive hosts. J Biotechnol 73 (1999) 235-242
69. Büttner M., and Rziha H.J. Parapoxviruses: from the lesion to the viral genome. J Vet Med Ser B 49 (2002) 7-16
70. Büttner M., Czerny C.P., Lehner K.H., and Wertz K. Interferon induction in peripheral blood mononuclear leukocytes of man and farm animals by poxvirus vector candidates and some poxvirus constructs. Vet Immunol Immunopathol 46 (1995) 237-250
71. Fachinger V., Schlapp T., Strube W., Schmeer N., and Saalmüller A. Poxvirus-induced immunostimulating effects on porcine leukocytes. J Virol 74 (2000) 7943-7951
72. Haig D.M., and McInnes C.J. Immunity and counter-immunity during infection with the parapoxvirus orf virus. Virus Res 88 (2002) 3-16
73. Kruse N., and Weber O. Selective induction of apoptosis in antigen-presenting cells in mice by Parapoxvirus ovis. J Virol 75 (2001) 4699-4704
74. Haig D., McInnes C.J., Deane D.L., Reid H., and Mercer A. The immune and inflammatory response to Orf virus. Comp Immunol Microbiol Infect Dis 20 (1997) 197-204
75. Robinson A., and Lyttle D.J. Parapoxviruses: their biology and potential as recombinant vaccines. In: Binns M.M., and Smith G.L. (Eds). Recombinant poxviruses (1992), CRC Press, Boca Raton, Florida 285-327
76. Castrucci G., Frigeri F., Osburn B.I., Ferrari M., Barreca F., and Salvatori D. Further investigations on the efficacy of a non specific defence inducer evaluated in calves exposed to infectious bovine rinotracheitis virus. Comp Immunol Microbiol Infect Dis 21 (1998) 155-163
77. BiukRudan N., Sver L., Valpotic I., Vrbanac I., Madic J., Zupancic Z., et al. Effect of Baypamun treatment on Aujeszky's disease virus (ADV) transmission in pigs. Acta Veterinaria Brno 73 (2004) 59-68
78. Terzić S., Jemeršić L., Lojkić M., Šver L., Valpotić I., Oršolić N., et al. Leukocyte subsets and specific antibodies in pigs vaccinated with a classical swine fever subunit (E2) vaccine and the attenuated ORF virus strain D1701. Acta Vet Hung 52 (2004) 151-161
79. Voigt H., Merant C., Wienhold D., Braun A., Hutet E., Le Potier M.F., et al. Efficient priming against classical swine fever with a safe glycoprotein E2 expressing Orf virus recombinant (ORFV VrV-E2). Vaccine 25 (2007) 5915-5926
80. Cottone R., Büttner M., Bauer B., Henkel M., Hettich E., and Rziha H.J. Analysis of genomic rearrangement and subsequent gene deletion of the attenuated Orf virus strain D1701. Virus Res 56 (1998) 53-67
81. Rziha H.J., Henke lM, Cottone R., Bauer B., Auge U., Götz F., et al. Generation of recombinant parapoxviruses: non-essential genes suitable for insertion and expression of foreign genes. J Biotechnol 83 (2000) 137-145
82. Davison A.J., Eberle R., Hayward G.S., McGeoch D.J., Minson A.C., Pellet P.E., et al. Herpesviridae virus taxonomy (2005), Elsevier Academic Press, New York
83. Kit M., Kit S., Little S.P., Di Marchi R.D., and Gale C. Bovine herpesvirus-1 (infectious rhinotracheitis virus)-based viral vector which expresses foot and mouth disease epitopes. Vaccine 9 (1991) 564-572
84. Kit S., Kit M., Di Marchi R.D., Little S.P., and Gale C. Modified-live infectious ovine rhinotracheitis virus vaccine expressing monomer and dimer forms of foot-and-mouth disease capsid protein epitopes on surface of hybrid virus particles. Arch Virol 120 (1991) 1-17
85. Kühnle G., Heinze A., Schmitt J., Giesow K., Taylor G., Morrison I., et al. The class II membrane glycoprotein of bovine respiratory syncytial virus, expressed from a synthetic open reading frame, is incorporated into virions of recombinant bovine herpesvirus 1. J Virol 72 (1998) 3804-3811
86. Taylor G., Rijsewijk F.A., Thomas L.H., Wyld S.G., Gaddum R.M., Cook R.S., et al. Resistance to bovine respiratory syncytial virus induced in calves by a recombinant bovine herpesvirus-1 expressing the attachment glycoprotein of BRSV. J Gen Virol 79 (1998) 1759-1767
87. Schmitt J., Becher P., Thiel H.J., and Keil G. Expression of bovine viral diarrhoea virus glycoprotein E2 by bovine herpesvirus-1 from a synthetic ORF and incorporation of E2 into recombinant virions. J Gen Virol 80 (1999) 2839-2848
88. Wang L., Whitbeck J.C., Lawrence W.C., Volgin D.V., and Bello L. Expression of the genomic form of the bovine viral diarrhea virus E2 ORF in a bovine herpesvirus-1 vector. Virus Genes 27 (2003) 83-91
89. Kweon C.H., Kang S.W., Choi E.J., and Kang Y.B. Bovine herpes virus expressing envelope protein (E2) of bovine viral diarrhea virus as a vaccine candidate. J Vet Med Sci 61 (1999) 395-401
90. Kit S., Otsuka H., and Kit M. Expression of porcine pseudorabiesvirus genes by bovine herpesvirus-1 (infectious rhinotracheitis virus) vector. Arch Virol 124 (1992) 1-20
91. Otsuka H., Xuan X., Shibata I., and Mori M. Protective immunity of bovine herpesvirus-1 (BHV-1) recombinants which express pseudorabies virus (PRV) glycoproteins gB, gC, gD, and gE. J Vet Med Sci 58 (1996) 8219-8224
92. Ikeda Y., Shibata I., Xuan X., Matsumoto Y., and Otsuka H. Immunogenic properties of a bovine herpesvirus-1 recombinant expressing major pseudorabies virus (PRV) glycoproteins in combination. J Vet Med Sci 62 (2000) 849-859
93. Takashima Y., Xuan X., Kimata I., Iseki M., Kodama Y., Nagane N., et al. Recombinant bovine herpesvirus-1 expressing p23 protein of Cryptosporidium parvum induces neutralizing antibodies in rabbits. J Parasitol 89 (2003) 276-282
94. Xuan X., Tuchiya K., Sato I., Nishikawa Y., Onoderaz Y., Takashima Y., et al. Biological and immunological properties of rabies virus glycoprotein expressed by canine herpesvirus vector. Vaccine 16 (1998) 969-976
95. Nishikawa Y., Ikeda H., Fukumoto S., Xuan X., Nagasawa H., Otsuka H., et al. Immunization of dogs with a canine herpesvirus vector expressing Neospora caninum surface protein, NcSRS2. Int J Parasitol 30 (2000) 1167-1171
96. Willemse M.J., van Schoeneveld S.H., Chalmers W.S., and Sondermeijer P.J. Vaccination against feline leuaemia using a new feline herpesvirus type 1 vector. Vaccine 14 (1996) 1511-1516
97. Wardley R.C., Berlinski P.J., Thomsen D.R., Meyer A.L., and Post L.E. The use of feline herpesvirus as vaccine vectors for the gag and enc genes of feline leukemia virus. J Gen Virol 73 (1992) 1811-1818
98. Mishima N., Xuan X., Yokoyama N., Igarashi I., Fujisaki K., Nagasawa H., et al. Recombinant feline herpesvirus type 1 expressing Toxoplasma gondii ROP2 antigen inducible protective immunity in cats. Parasitol Res 88 (2002) 144-149
99. Yokoyama N., Maeda K., Tohya Y., Kawaguchi Y., Fujita K., and Mikami T. Recombinant feline herpesvirus type 1 expressing immunogenic proteins inducible virus neutralizing antibody against feline calicivirus in cats. Vaccine 14 (1996) 1657-1663
100. Sato E., Yokoyama N., Maeda K., Inoshima Y., Kohmoto M., Ikeda Y., et al. Construction of a recombinant feline herpesvirus type 1 expressing gag precursor protein of feline immunodeficiency virus. Arch Virol 143 (1998) 453-466
101. Sato E., Yokoyama N., Miyazawa T., Maeda K., Ikeda Y., Nishimura Y., et al. Efficient expression of the envelope protein of feline immunodeficiency virus in a recombinant feline herpesvirus type 1 (FHV-1) using the gC promoter of FHV-1. Virus Res 70 (2000) 13-23
102. Sonoda K., Sakaguchi M., Okamura H., Yokogawa K., Tokunaga E., Tokiyoshi S., et al. Development of an effective polyvalent against both Marek's and Newcastle disease virus type 1 in commercial chickens with maternal antibodies. J Virol 74 (2000) 3217-3236
103. Tsukamoto K., Kojima C., Komori Y., Tanimura N., Mase M., and Yamaguchi S. Protection of chickens against very virulent infectious bursal disease (IBDV) and Marek's disease virus (MDV) with a recombinant MDV expressing IBDV VP2. Virology 257 (1999) 352-362
104. Darteil R., Bublot M., Laplace E., Bouquet J.F., Audonnet J.C., and Rivière M. Herpesvirus of turkey recombinant viruses expressing infectious bursal disease virus (IBDV) VP2 immunogen induce protection against an IBDV virulent challenge in chickens. Virology 211 (1995) 481-490
105. Tsukamoto K., Saito S., Saeki S., Sato T., Tanimura N., Isobe T., et al. Complete, long lasting protection against lethal infectious busal disease virus challenge by a single vaccination with an avian herpesvirus vector expressing VP2 antigens. J Virol 76 (2002) 5637-5645
106. Bublot M., Pritchard N., Le Gros F.-X., and Goutebroze S. Use of a vectored vaccine against infectious bursal disease of chickens in the faced of high-titred maternally derived antibody. J Comp Pathol 137 (2007) S81-S84
107. Lüschow D., Werner O., Mettenleiter T.C., and Fuchs W. Protection of chickens from lethal avian influenza A virus infection by live-virus vaccination with infectious laryngotracheitis virus recombinants expressing the (H5) gene. Vaccine 19 (2001) 4249-4259
108. Van Zijl M., Wensvoort G., de Kluyver E., Hulst M., van der Gulden H., Gielkens A., et al. Live attenuated pseudorabiesvirus expressing envelope glycoproteon E1 of hog cholera virus protects swine against both pseudorabiesvirus and hog cholera. J Virol 65 (1991) 2761-2765
109. Xu G., Xu X., Li Z., He Q., Wu B., Sun S., et al. Construction of recombinant pseudorabiesvirus expressing NS1 protein of Japanese encephalitis (SA14-14-2) virus and its safety and immunogenicity. Vaccine 22 (2004) 1846-1853
110. Qian P., Li X.-M., Jin M.-L., Peng G.-Q., and Chen H.-C. An approach to a FMD vaccine based on genetic engineered attenuated pseudorabies virus: one experiment using VP1 gene alone generates an antibody responds on FMD and pseudorabies in swine. Vaccine 22 (2004) 2129-2136
111. Tian Z.J., Qiu H.J., Ni J.Q., Zhou Y.J., Cai X.H., Zhou G.H., et al. Construction and Characterization of a recombinant pseudorabiesvirus expressing porcine reproductive and respiratory syndrome virus GP5. Yi Chuan Xue Bao 32 (2005) 1248-1255
112. Qiu H.J., Tian Z.J., Tong G.Z., Zhou Y.J., Ni J.Q., Luo Y.Z., et al. Protective immunity induced by a recombinant pseudorabies virus expressing the GP5 of porcine reproductive and respiratory syndrome virus in piglets. Vet Immunol Immunopathol 106 (2005) 309-319
113. Jiang Y., Fang L., Xiao S., Zhang H., Pan Y., Luo R., et al. Immunogenicity and protective efficacy of recombinant pseudorabies virus expressing the two major membrane-associated proteins of porcine reproductive and respiratory syndrome virus. Vaccine 25 (2007) 547-560
114. Yin J., Ren X., Tian Z.J., and Li Y. Assembly of pseudorabies virus genome-based transfer vehicle carrying major antigen sites of S gene of transmissible gastroenteritis virus: potential perspective for developing live vector vaccines. Biologicals 35 (2007) 55-61
115. Song Y., Jin M., Zhang S., Xu X., Xiao S., Cao S., et al. Generation and immunogenicity of a recombinant pseudorabies virus expressing capprotein of porcine circovirus type 2. Vet Mic 119 (2007) 97-104
116. Hong Q., Qian P., Li X.M., Yu X.L., and Chen H.C. A recombinant pseudorabies virus co-expressing capsid proteins precursor P1-2A of FMDV and VP2 protein of porcine parvovius: a tivalent vaccine candidate. Biotechnol Lett 29 (2007) 1766-1783
117. Yuan Z., Zhang S., Liu Y., Zhang F., Fooks A.R., Li Q., et al. A recombinant pseudorabies virus expressing rabies virus glycoproten: safety and immunogenicity in dogs. Vaccine 26 (2008) 1314-1321
118. Tian Z.J., Zhou G.H., Zheng B.L., Qiu H.J., Ni J.Q., Yang H.L., et al. A recombinant pseudorabies virus encoding the HA gene from H3N2 subtype swine influenza virus protects mice from virulent challenge. Vet Immunol Immunopathol 111 (2006) 211-218
119. Adler H., Messerle M., and Koszinowski U.H. Cloning of herpesviral gnomes as bacterial artificial chromosomes. Rev Med Virol 13 (2003) 111-121
120. Rosas C.T., König P., Beer M., Dubovi E.J., Tischer B.K., and Osterrieder N. Evaluation of the vaccine potential of an equine herpesvirus type 1 vector expressing bovine viral diarrhea virus structural proteins. J Gen Virol 88 (2007) 748-757
121. Rosas C.T., Tischer B.K., Perkins G.A., Wagner B., Goodman L.B., and Osterrieder N. Live-attenuated recombinant equine herpesvirus type 1 (EHV-1) induces a neutralizing ntibody response against West Nile virus (WNV). Virus Res 125 (2007) 69-78
122. Donofrio G., Sartori C., Ravanetti L., Cavirani S., Gillet L., Vanderplasschen A., et al. Establishment of a bovine herpesvirus 4 based vector expressing a secreted form of the bovine viral diarrhoea virus structural glycoprotein E2 for immunization purposes. BMC Biotechnol 7 (2007) 68-79
123. Donofrio G., Cavirani S., Vanderplasschen A., Gillet L., and Flammini C. Recombinant bovine herpesvirus 4 (BoHV-4) expressing glycoprotein D of BoHV-1 is immunogenic and elicits serum-neutralizing antibodies against BoHV-1 in a rabbit model. Clin Vacc Immunol 13 (2006) 1246-1254
124. Klonjkowski B., Denesvre C., and Eloit M. Adenoviral vectors for vaccines. In: Prem Seth (Ed). Adenoviruses: basic biology to gene therapy vol. 17 (1999), RG Landes Company, Austin Texas, USA 163-173
125. Shiver J.W., Fu T.M., Chen L., Casimiro D.R., Davies M.E., Evans R.K., et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415 January (6869) (2002) 331-335
126. Millar J., Dissanayake D., Yang T.C., Grinshtein N., Evelegh C., Wan Y., et al. The magnitude of the CD8+ T cell response produced by recombinant virus vectors is a function of both the antigen and the vector. Cell Immunol 250 November-December (1-2) (2007) 55-67
127. Muruve D.A. The innate immune response to adenovirus vectors. Hum Gene Ther 15 December (12) (2004) 1157-1166
128. McCoy R.D., Davidson B.L., Roessler B.J., Huffnagle G.B., Janich S.L., Laing T.J., et al. Pulmonary inflammation induced by incomplete or inactivated adenoviral particles. Hum Gene Ther 6 December (12) (1995) 1553-1560
129. Liu Q., Zaiss A.K., Colarusso P., Patel K., Haljan G., Wickham T.J., et al. The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors. Hum Gene Ther 14 May (7) (2003) 627-643
130. Muruve D.A., Cotter M.J., Zaiss A.K., White L.R., Liu Q., Chan T., et al. Helper-dependent adenovirus vectors elicit intact innate but attenuated adaptive host immune responses in vivo. J Virol 78 June (11) (2004) 5966-5972
131. Roth M.D., Cheng Q., and Harui Aea. Helper-dependent adenoviral vectors efficiently express transgenes in human dendritic cells but still stimulate antiviral immune responses. J Immunol 169 8 (2002) 4651-4656
132. Molinier-Frenkel V., Lengagne R., Gaden F., Hong S.S., Choppin J., Gahery-Segard H., et al. Adenovirus hexon protein is a potent adjuvant for activation of a cellular immune response. J Virol 76 January (1) (2002) 127-135
133. Santra S., Seaman M.S., Xu L., Barouch D.H., Lord C.I., Lifton M.A., et al. Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J Virol 79 May (10) (2005) 6516-6522
134. Hensley S.E., Giles-Davis W., McCoy K.C., Weninger W., and Ertl H.C. Dendritic cell maturation, but not CD8+ T cell induction, is dependent on type I IFN signaling during vaccination with adenovirus vectors. J Immunol 175 9 (2005) 6032-6041
135. Casimiro D.R., Wang F., and Schleif WAea. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag. J Virol 79 24 (2005) 15547-15555
136. Yang T.C., Millar J., and Tea Groves. The CD8+ T cell population elicited by recombinant adenovirus displays a novel partially exhausted phenotype associated with prolonged antigen presentation that nonetheless provides long-term immunity. J Immunol 176 1 (2006) 200-210
137. Yang T.C., Millar J., and Tea G. On the role of CD4+ T cells in the CD8+ T-cell response elicited by recombinant adenovirus vaccines. Mol Ther 15 5 (2007) 997-1006
138. Tatsis N., Fitzgerald J.C., Reyes-Sandoval A., Harris-McCoy K.C., Hensley S.E., Zhou D., et al. Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. Blood 110 September (6) (2007) 1916-1923
139. Tatsis N., and Ertl H.C. Adenoviruses as vaccine vectors. Mol Ther 10 October (4) (2004) 616-629
140. Santosuosso M., McCormick S., and Xing Z. Adenoviral vectors for mucosal vaccination against infectious diseases. Viral Immunol 18 2 (2005) 283-291
141. Barouch D.H., and Nabel G.J. Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum Gene Ther 16 February (2) (2005) 149-156
142. Ferreira T.B., Alves P.M., Aunins J.G., and Carrondo M.J. Use of adenoviral vectors as veterinary vaccines. Gene Ther 12 October (Suppl. 1) (2005) S73-S83
143. Moraes M.P., Mayr G.A., Mason P.W., and Grubman M.J. Early protection against homologous challenge after a single dose of replication-defective human adenovirus type 5 expressing capsid proteins of foot-and-mouth disease virus (FMDV) strain A24. Vaccine 20 February (11-12) (2002) 1631-1639
144. Pacheco J.M., Brum M.C., Moraes M.P., Golde W.T., and Grubman M.J. Rapid protection of cattle from direct challenge with foot-and-mouth disease virus (FMDV) by a single inoculation with an adenovirus-vectored FMDV subunit vaccine. Virology 337 July (2) (2005) 205-209
145. Hammond J.M., and Johnson M.A. Porcine adenovirus as a delivery system for swine vaccines and immunotherapeutics. Vet J 169 January (1) (2005) 17-27
146. Both G.W. Ovine atadenovirus: a review of its biology, biosafety profile and application as a gene delivery vector. Immunol Cell Biol 82 2 (2004) 189-195
147. Zhi Y., Figueredo J., Kobinger G.P., Hagan H., Calcedo R., Miller J.R., et al. Efficacy of severe acute respiratory syndrome vaccine based on a nonhuman primate adenovirus in the presence of immunity against human adenovirus. Hum Gene Ther 17 May (5) (2006) 500-506
148. Singh N., Pandey A., Jayashankar L., and Mittal S.K. Bovine adenoviral vector-based H5N1 influenza vaccine overcomes exceptionally high levels of pre-existing immunity against human adenovirus. Mol Ther 16 May (5) (2008) 965-971
149. Hammond J.M., McCoy R.J., Jansen E.S., Morrissy C.J., Hodgson A.L., and Johnson M.A. Vaccination with a single dose of a recombinant porcine adenovirus expressing the classical swine fever virus gp55 (E2) gene protects pigs against classical swine fever. Vaccine 18 January (11-12) (2000) 1040-1050
150. Hammond J.M., Jansen E.S., Morrissy C.J., Goff W.V., Meehan G.C., Williamson M.M., et al. A prime-boost vaccination strategy using naked DNA followed by recombinant porcine adenovirus protects pigs from classical swine fever. Vet Microbiol 80 May (2) (2001) 101-119
151. Hammond J.M., Jansen E.S., Morrissy C.J., van der Heide B., Goff W.V., Williamson M.M., et al. Vaccination of pigs with a recombinant porcine adenovirus expressing the gD gene from pseudorabies virus. Vaccine 19 June (27) (2001) 3752-3758
152. Wuest T., Both G.W., Prince A.M., Hofmann C., and Loser P. Recombinant ovine atadenovirus induces a strong and sustained T cell response against the hepatitis C virus NS3 antigen in mice. Vaccine 22 July (21-22) (2004) 2717-2721
153. Zakhartchouk A.N., Pyne C., Mutwiri G.K., Papp Z., Baca-Estrada M.E., Griebel P., et al. Mucosal immunization of calves with recombinant bovine adenovirus-3: induction of protective immunity to bovine herpesvirus-1. J Gen Virol 80 May (Pt 5) (1999) 1263-1269
154. Li J., Faber M., Papaneri A., Faber M.L., McGettigan J.P., Schnell M.J., et al. A single immunization with a recombinant canine adenovirus expressing the rabies virus G protein confers protective immunity against rabies in mice. Virology 356 December (1-2) (2006) 147-154
155. Hu R., Zhang S., Fooks A.R., Yuan H., Liu Y., Li H., et al. Prevention of rabies virus infection in dogs by a recombinant canine adenovirus type-2 encoding the rabies virus glycoprotein. Microbes Infect 8 April (4) (2006) 1090-1097
156. Hu R.L., Liu Y., Zhang S.F., Zhang F., and Fooks A.R. Experimental immunization of cats with a recombinant rabies-canine adenovirus vaccine elicits a long-lasting neutralizing antibody response against rabies. Vaccine 25 July (29) (2007) 5301-5307
157. Yang S., Xia X., Qiao J., Liu Q., Chang S., Xie Z., et al. Complete protection of cats against feline panleukopenia virus challenge by a recombinant canine adenovirus type 2 expressing VP2 from FPV. Vaccine 26 March (11) (2008) 1482-1487
158. Liu Y., Hu R., Zhang S., Zhang F., Li Z., Wei X., et al. Expression of the foot-and-mouth disease virus VP1 protein using a replication-competent recombinant canine adenovirus type 2 elicits a humoral antibody response in a porcine model. Viral Immunol 19 Summer (2) (2006) 202-209
159. Fischer L., Tronel J.P., Pardo-David C., Tanner P., Colombet G., Minke J., et al. Vaccination of puppies born to immune dams with a canine adenovirus-based vaccine protects against a canine distemper virus challenge. Vaccine 20 October (29-30) (2002) 3485-3497
160. Francois A., Chevalier C., Delmas B., Eterradossi N., Toquin D., Rivallan G., et al. Avian adenovirus CELO recombinants expressing VP2 of infectious bursal disease virus induce protection against bursal disease in chickens. Vaccine 22 June (17-18) (2004) 2351-2360
161. Jones K.E., Patel N.G., Levy M.A., Storeygard A., Balk D., Gittleman J.L., et al. Global trends in emerging infectious diseases. Nature 451 February (7181) (2008) 990-993
162. Top Jr. F.H., Buescher E.L., Bancroft W.H., and Russell P.K. Immunization with live types 7 and 4 adenovirus vaccines. II. Antibody response and protective effect against acute respiratory disease due to adenovirus type 7. J Infect Dis 124 August (2) (1971) 155-160
163. Top Jr. F.H., Dudding B.A., Russell P.K., and Buescher E.L. Control of respiratory disease in recruits with types 4 and 7 adenovirus vaccines. Am J Epidemiol 94 August (2) (1971) 142-146
164. Top Jr. F.H., Grossman R.A., Bartelloni P.J., Segal H.E., Dudding B.A., Russell P.K., et al. Immunization with live types 7 and 4 adenovirus vaccines. I. Safety, infectivity, antigenicity, and potency of adenovirus type 7 vaccine in humans. J Infect Dis 124 August (2) (1971) 148-154
165. Kitchen L.W., and Vaughn D.W. Role of U.S. military research programs in the development of U.S.-licensed vaccines for naturally occurring infectious diseases. Vaccine 25 October (41) (2007) 7017-7030
166. Vos A., Neubert A., Pommerening E., Muller T., Dohner L., Neubert L., et al. Immunogenicity of an E1-deleted recombinant human adenovirus against rabies by different routes of administration. J Gen Virol 82 September (Pt 9) (2001) 2191-2197
167. Hammond J.M., Jansen E.S., Morrissy C.J., Williamson M.M., Hodgson A.L., and Johnson M.A. Oral and sub-cutaneous vaccination of commercial pigs with a recombinant porcine adenovirus expressing the classical swine fever virus gp55 gene. Arch Virol 146 9 (2001) 1787-1793
168. Hammond J.M., Jansen E.S., Morrissy C.J., Hodgson A.L., and Johnson M.A. Protection of pigs against 'in contact' challenge with classical swine fever following oral or subcutaneous vaccination with a recombinant porcine adenovirus. Virus Res 97 November (2) (2003) 151-157
169. Tuboly T., and Nagy E. Construction and characterization of recombinant porcine adenovirus serotype 5 expressing the transmissible gastroenteritis virus spike gene. J Gen Virol 82 January (Pt 1) (2001) 183-190
170. Babiuk L.A., and Tikoo S.K. Adenoviruses as vectors for delivering vaccines to mucosal surfaces. J Biotechnol 83 September (1-2) (2000) 105-113
171. Johnson M.A., Pooley C., Ignjatovic J., and Tyack S.G. A recombinant fowl adenovirus expressing the S1 gene of infectious bronchitis virus protects against challenge with infectious bronchitis virus. Vaccine 21 June (21-22) (2003) 2730-2736
172. Xiang Z.Q., Gao G.P., Reyes-Sandoval A., Li Y., Wilson J.M., and Ertl H.C. Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. J Virol 77 October (20) (2003) 10780-10789
173. Mercier G.T., Nehete P.N., Passeri M.F., Nehete B.N., Weaver E.A., Templeton N.S., et al. Oral immunization of rhesus macaques with adenoviral HIV vaccines using enteric-coated capsules. Vaccine 25 December (52) (2007) 8687-8701
174. Lubeck M.D., Davis A.R., Chengalvala M., Natuk R.J., Morin J.E., Molnar-Kimber K., et al. Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus. Proc Natl Acad Sci U S A 86 September (17) (1989) 6763-6767
175. Ertl H.C. Immunological insights from genetic vaccines. Virus Res 111 July (1) (2005) 89-92
176. Zhou D., Cun A., Li Y., Xiang Z., and Ertl H.C. A chimpanzee-origin adenovirus vector expressing the rabies virus glycoprotein as an oral vaccine against inhalation infection with rabies virus. Mol Ther 14 November (5) (2006) 662-672
177. Mutwiri G., Bateman C., Baca-Estrada M.E., Snider M., and Griebel P. Induction of immune responses in newborn lambs following enteric immunization with a human adenovirus vaccine vector. Vaccine 19 December (9-10) (2000) 1284-1293
178. Cheng X., Ming X., and Croyle M.A. PEGylated adenoviruses for gene delivery to the intestinal epithelium by the oral route. Pharm Res 20 9 (2003) 1444-1451
179. Tucker S.N., Tingley D.W., and Scallan C.D. Oral adenoviral-based vaccines: historical perspective and future opportunity. Expert Rev Vaccines 7 1 (2008) 25-31
180. Lin S.W., Cun A.S., Harris-McCoy K., and Ertl H.C. Intramuscular rather than oral administration of replication-defective adenoviral vaccine vector induces specific CD8+ T cell responses in the gut. Vaccine 25 March (12) (2007) 2187-2193
181. Oomura K., Xin K.Q., Takakura M., Shinoda K., Jounai N., and Okuda K. Oral administration of the adenovirus vector induces systemic immunity rather than intestinal mucosal immunity. Vaccine 24 8 (2006) 1045-1046
182. Theilmann D.A., Blissard G.W., Bonning B.J.J., O'Reilly D.R., Rohrmann G.F., Thiem S., et al. Baculoviridae. In: Fauquet C.M., Mayo M.A., Maniloff J., Desselberger U., and Ball L.A. (Eds). Virus taxonomy: eighth report of the International Committee on Taxonomy of Viruses (2005), Elsevier Academic Press, New York 177-185
183. Wood H.A. Development and testing of genetically improved baculovirus insecticides. In: Shuler M.L., Wood H.A., Granados R.R., and Hammer D.A. (Eds). Baculovirus expression systems and biopesticides (1995), Wiley-Liss, New York 91-102
184. Smith G.E., Summers M.D., and Fraser M.J. Production of human beta interferon in insect cells infected with a baculovirus expression vector. Mol Cell Biol 3 (1983) 2156-2165
185. Hofmann C., Sandig V., Jennings G., Rudolf M., Schlag P., and Strauss M. Efficient gene transfer into human hepatocytes by baculovirus vectors. Proc Natl Acad Sci U S A 92 (1995) 10099-10103
186. Hofmann C., and Strauss M. Baculovirus-mediated gene transfer in the presence of human serum or blood facilitated by inhibition of the complement system. Gene Ther 5 (1998) 531-536
187. Boyce F.M., and Bucher N.L. Baculovirus-mediated gene transfer into mammalian cells. Proc Natl Acad Sci U S A 93 (1996) 2348-2352
188. Pfoh L.J., Worley J.F.R., Condrey J.P., An G., Apolito C.J., Kost T.A., et al. Titration of KATP channel expression in mammalian cells utilizing recombinant baculovirus transduction. Receptors Channels 8 (2002) 99-111
189. Kost T.A., and Condreay J.P. Recombinant baculoviruses as mammalian cell gene-delivery vectors. Trends Biotechnol 20 (2002) 173-180
190. Ping W., Ge J., Li S., Zhou H., Wang K., Feng Y., et al. Baculovirus-mediated gene expression in chicken primary cells. Avian Dis 50 (2006) 59-63
191. Song J., Liang C., and Chen X. Transduction of avian cells with recombinant baculovirus. J Virol Methods 135 (2006) 157-162
192. Leisy D.J., Lewis T.D., Leong J.A., and Rohrmann G.F. Transduction of cultured fish cells with recombinant baculoviruses. J Gen Virol 84 (2003) 1173-1178
193. Wagle M., and Jesuthasan S. Baculovirus-mediated gene expression in zebrafish. Mar Biotechnol 5 (2003) 58-63
194. Hu Y.C. Baculovirus as a highly efficient expression vector in insect and mammalian cells. Acta Pharmacologica Sinica 26 (2005) 405-416
195. Kost T.A., Condrey J.P., Ames R.S., Rees S., and Romanos M.A. Implementation of BacMam virus gene delivery in a drug discovery setting. Drug Discovery Today 12 (2007) 396-401
196. Sandig V., Hoffmann C., Steinert S., Jennings G., Schlag P., and Strauss M. Gene transfer into hepatocytes and human liver tissue by baculovirus vectors. Hum Gene Ther 7 (1996) 1937-1945
197. Hüser A., Rudolph M., and Hofmann C. Incorporation of decay-accelerating factor into the baculovirus envelope generates complement-resistant gene transfer vectors. Nat Biotechnol 19 (2001) 451-455
198. Tani H., Limn C.K., Yap C.C., Onishi M., Nozaki M., Nishimune Y., et al. In vitro and in vivo gene delivery by recombinant baculoviruses. J Virol 77 (2003) 9799-9808
199. Pieroni L., Maione D., and La Monica N. In vivo gene transfer in mouse sceletal muscle mediated by baculovirus vectors. Hum Gene Ther 12 (2001) 871-881
200. Kaikkonen M.U., Räty J.K., Airenn K.J., Wirth T., Heikure T., and Ylä-Herttuala. Truncated vesicular stomatitis viru G protein improves baculovirus transduction efficiency in vitro and in vivo. Gene Ther 13 (2006) 304-312
201. Aoki H., Sakoda Y., Jukuroki K., Takada A., Kida H., and Fukusho A. Induction of antibodies in mice by a recombinant baculovirus expressing pseudorabies virus glycoprotein B in mammalian cells. Vet Mic 68 (1999) 197-207
202. Strauss R., Hüser A., Ni S., Tuve S., Kiviat N., Sow P., et al. Baculovirus-based vaccination vectors allow for efficient induction of immune responses against plasmodium falciparum circumsporozoite protein. Mol Ther 15 (2007) 193-202
203. Gronowski A.M., Hilbert D.M., Sheehan K.C.F., Garotta G., and Schreiber R.D. Baculovirus stimulates antiviral effects in mammalian cells. J Virol 73 (1999) 9944-9951
204. Abe T., Takahashi H., Hamazaki H., Miyano-Kurosaki N., Matsuura Y., and Takaku H. Baculovirus induces an innate immune response and confers protection from lethal influenza virus infection in mice. J Immunol 171 (2003) 1131-1139
205. Hervas-Stubbs S., Rueda P., Lopez L., and Leclerc C. Insect baculoviruses strongly potentiate adaptive immune responses by inducing type I IFN J Immunol 178 (2007) 2361-2369
206. Facciabene A., Aurisicchio L., and La Monica N. Baculovirus vectors elicit antigen-specific immune responses in mice. J Virol 78 (2004) 8663-8672
207. Wang S., Fang L., Fan H., Jiang Y., Pan Y., Luo R., et al. Construction and immunogenicity of pseudotype baculovirus expressing GP5 and M protein of porcine reproductive and respiratory syndrome virus. Vaccine 25 (2007) 8220-8227
208. Ojala K., Mottershead D.G., Suokko A., and Oker-Blom C. Specific binding of baculoviruses displaying gp64 fusion proteins to mammalian cells. Biochem Biophys Res Commun 284 (2001) 777-784
209. Räty J.K., Airenne K.J., Marttila A.T., Marjomäki V., Hytönen V.P., Lehtoainen P., et al. Enhanced gene delivery by avidin-displaying baculovirus. Mol Ther 9 (2004) 282-291
210. Kitagawa Y., Tani H., Limn C.K., Matsunaga T.M., Moriishi K., and Matsuura Y. Ligand-directed gene targeting to mammalian cels by pseudotype baculoviruses. J Virol 79 (2005) 3639-3652
211. Zhou J., and Blissard G.W. Display of heterologous proteins on gp64null baculovirus virions and enhanced budding mediated by a vesicular stomatitis virus G-stem construct. J Virol 82 (2008) 1368-1377
212. Ge J., Huang Y., Hu X., and Zhong J. A surface modified baculovirus vector with improved gene delivery to B-lymphocytes. J Biotechnol 129 (2007) 367-372
213. Mähönen A.J., Airenne K.J., Purola S., Peltomaa E., Kaikkonen M.U., Riekkinen M.S., et al. Post-transcriptional regulatory element boosts baculovirus-mediated gene expression in vertebrate cells. J Biotechnol 131 (2007) 1-8
214. Murphy F.A., Fauquet C.M., Bishop D.H.L., Ghabrial S.A., Jarvis A.W., Martelli G.P., et al. Virus taxonomy (1995), Springer-Verlag, New York
215. Conzelmann TRaS M. Rescue of synthetic genome analogs of rabies virus by plasmid-encoded DNA. J Virol 68 (1994) 713-719
216. Palese P., Zheng H., Engelhardt O.G., Pleschka S., and Garcia-Sastre A. Negative-strand RNA viruses: genetic engineering and application. Proc Natl Acad Sci U S A 93 (1996) 11354-11358
217. Palese P., Zheng H., Engelhardt O.G., Pleschka S., and Garcia-Sastre A. RNA virus vectors: where are we and where do we need to go?. Proc Natl Acad Sci U S A 95 (1998) 12750-12752
218. Neumann G., and Kawaoka Y. Genetic engineering of influenza and other negative-strand RNA viruses containing segmented genomes. Adv Virus Res 53 (1999) 265-300
219. Neumann G., Whitt M.A., and Kawaoka Y. A decade after the generation of a negative-sense RNA virus from cloned cDNA - what have we learned?. J Gen Virol 83 November (Pt 11) (2002) 2635-2662
220. Mayo M.A. A summary of taxonomic changes recently approved by ICTV. Arch Virol 147 August (8) (2002) 1655-1663
221. Wang L.F., Chua K.B., Yu M., and Eaton B.T. Genome diversity of emerging paramyxoviruses. Curr Genomics 4 (2003) 263-273
222. Lamb R.A., and Kolakofsky D. In: Knipe D.M., and Howley P.M. (Eds). The viruses and their replication (2001), Lippincott Williams & Wilkins, Philadelphia
223. Bukreyev A., Camargo E., and Collins P.L. Recovery of infectious respiratory syncytial virus expressing an additional, foreign gene. J Virol 70 October (10) (1996) 6634-6641
224. Hasan M.K., Kato A., Shioda T., Sakai Y., Yu D., and Nagai Y. Creation of an infectious recombinant Sendai virus expressing the firefly luciferase gene from the 3′ proximal first locus. J Gen Virol 78 November (Pt 11) (1997) 2813-2820
225. Baron M., Foster-Cuevas M., Baron J., and Barrett T. Expression in cattle of epitopes of a heterologous virus using a recombinant rinderpest virus. J Gen Virol 80 8 (1999) 2031-2039
226. He B., Paterson R.G., Ward C.D., and Lamb R.A. Recovery of infectious SV5 from cloned DNA and expression of a foreign gene. Virology 237 October (2) (1997) 249-260
227. Sakai Y., Kiyotani K., Fukumura M., Asakawa M., Kato A., Shioda T., et al. Accommodation of foreign genes into the Sendai virus genome: sizes of inserted genes and viral replication. FEBS Lett 456 August (2) (1999) 221-226
228. Spielhofer P., Bachi T., Fehr T., Christiansen G., Cattaneo R., Kaelin K., et al. Chimeric measles viruses with a foreign envelope. J Virol 72 March (3) (1998) 2150-2159
229. Brandler S., and Tangy F. Recombinant vector derived from live attenuated measles virus: potential for flavivirus vaccines. Comp Immunol Microbiol Infect Dis 31 2-3 (2008) 271-291
230. van Oirschot J.T. Diva vaccines that reduce virus transmission. J Biotechnol 73 August (2-3) (1999) 195-205
231. Peeters B.P., de Leeuw O.S., Verstegen I., Koch G., and Gielkens A.L. Generation of a recombinant chimeric Newcastle disease virus vaccine that allows serological differentiation between vaccinated and infected animals. Vaccine 19 February (13-14) (2001) 1616-1627
232. Mebatsion T., Koolen M.J., de Vaan L.T., de Haas N., Braber M., Romer-Oberdorfer A., et al. Newcastle disease virus (NDV) marker vaccine: an immunodominant epitope on the nucleoprotein gene of NDV can be deleted or replaced by a foreign epitope. J Virol 76 October (20) (2002) 10138-10146
233. Reynolds D.L., and Maraqa A.D. Protective immunity against Newcastle disease: the role of cell-mediated immunity. Avian Dis 44 January-March (1) (2000) 145-154
234. Ward M.D., Fuller F.J., Mehrotra Y., and De Buysscher E.V. Nucleotide sequence and vaccinia expression of the nucleoprotein of a highly virulent, neurotropic strain of Newcastle disease virus. Avian Dis 44 January-March (1) (2000) 34-44
235. Ge J., Deng G., Wen Z., Tian G., Wang Y., Shi J., et al. Newcastle disease virus-based live attenuated vaccine completely protects chickens and mice from lethal challenge of homologous and heterologous H5N1 avian influenza viruses. J Virol 81 January (1) (2007) 150-158
236. Parida S., Mahapatra M., Kumar S., Das S.C., Baron M.D., Anderson J., et al. Rescue of a chimeric rinderpest virus with the nucleocapsid protein derived from peste-des-petits-ruminants virus: use as a marker vaccine. J Gen Virol 88 July (Pt 7) (2007) 2019-2027
237. Das S.C., Baron M.D., and Barrett T. Recovery and characterization of a chimeric rinderpest virus with the glycoproteins of peste-des-petits-ruminants virus: homologous F and H proteins are required for virus viability. J Virol 74 October (19) (2000) 9039-9047
238. Park M.S., Steel J., Garcia-Sastre A., Swayne D., and Palese P. Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle disease. Proc Natl Acad Sci U S A 103 May (21) (2006) 8203-8208
239. Stope M.B., Karger A., Schmidt U., and Buchholz U.J. Chimeric bovine respiratory syncytial virus with attachment and fusion glycoproteins replaced by bovine parainfluenza virus type 3 hemagglutinin-neuraminidase and fusion proteins. J Virol 75 October (19) (2001) 9367-9377
240. Mahapatra M., Parida S., Baron M.D., and Barrett T. Matrix protein and glycoproteins F and H of Peste-des-petits-ruminants virus function better as a homologous complex. J Gen Virol 87 July (Pt 7) (2006) 2021-2029
241. McKenna P.M., McGettigan J.P., Pomerantz R.J., Dietzschold B., and Schnell M.J. Recombinant rhabdoviruses as potential vaccines for HIV-1 and other diseases. Curr HIV Res 1 April (2) (2003) 229-237
242. Schnell M.J., Mebatsion T., and Conzelmann K.K. Infectious rabies viruses from cloned cDNA. EMBO J 13 September (18) (1994) 4195-4203
243. Lawson N.D., Stillman E.A., Whitt M.A., and Rose J.K. Recombinant vesicular stomatitis viruses from DNA. Proc Natl Acad Sci U S A 92 May (10) (1995) 4477-4481
244. Whelan S.P., Ball L.A., Barr J.N., and Wertz G.T. Efficient recovery of infectious vesicular stomatitis virus entirely from cDNA clones. Proc Natl Acad Sci U S A 92 August (18) (1995) 8388-8392
245. Ezelle H.J., Markovic D., and Barber G.N. Generation of hepatitis C virus-like particles by use of a recombinant vesicular stomatitis virus vector. J Virol 76 December (23) (2002) 12325-12334
246. Schnell M.J., Buonocore L., Whitt M.A., and Rose J.K. The minimal conserved transcription stop-start signal promotes stable expression of a foreign gene in vesicular stomatitis virus. J Virol 70 April (4) (1996) 2318-2323
247. Mebatsion T., Schnell M.J., Cox J.H., Finke S., and Conzelmann K.K. Highly stable expression of a foreign gene from rabies virus vectors. Proc Natl Acad Sci U S A 93 July (14) (1996) 7310-7314
248. Feldmann H.J., Jones S.M., Daddario-DiCaprio K.M., Geisbert J.B., Stroher U., Grolla A., et al. Effective post-exposure treatment of Ebola infection. PLoS pathogens 3 January (1) (2007) e2
249. Kohl W., Grone A., Moennig V., and Herrler G. Expression of the surface glycoprotein E2 of Bovine viral diarrhea virus by recombinant vesicular stomatitis virus. J Gen Virol 88 January (Pt 1) (2007) 157-165
250. Geisbert T.W., Jones S., Fritz E.A., Shurtleff A.C., Geisbert J.B., Liebscher R., et al. Development of a new vaccine for the prevention of Lassa fever. PLoS Med 2 June (6) (2005) e183
251. Conzelmann K.K., Cox J.H., Schneider L.G., and Thiel H.J. Molecular cloning and complete nucleotide sequence of the attenuated rabies virus SAD B19. Virology 175 April (2) (1990) 485-499
252. Ball L.A., Pringle C.P., Flanagan B., Perepelitsa V.P., and Wertz G.W. Phenotypic consequences of rearranging the P, M, and G genes of vesicular stomatitis virus. J Virol 73 June (6) (1999) 4705-4712
253. Bridgen A., and Elliot R.M. Rescue of a segmented negative strand RNA virus entirely from cloned cDNA. PNAS 93 (1996) 15400-15404
254. Blakqori G., and Weber F. Efficient cDNA-based rescue of LaCrosse bunyaviruses expressing or lacking the structural protein NSs. J Virol 79 (2004) 10420-10428
255. Ikegami T., Won S., Peters C.J., and Makino S. Rescue of infectious Rift Valley fever virus entirely from cDNA, analysis of virus lacking the NSs gene, and expression of a foreign gene. J Virol 80 (2006) 2933-2940
256. Lundstrom K. Alphavirus vectors: applications for DNA vaccine production and gene expression. Intervirology 43 (2000) 247-257
257. Balasuriya U.B., Heidner H.W., Davis N.L., Wagner H.M., Hullinger P.J., and Hedges J.F.E.A. Alphavirus replicon particles expressing the two major envelope proteins of equine arteritis virus induce high level protection against challenge with virulent virus in vaccinated horses. Vaccine 20 (2002) 1609-1617
258. Vajdy M., Gardner J.P., Neidelman J., Cuadra L., Greer C., and Perri S. Gag-specific vaginal immunity and protection after local immunizations with Sindbis virus-based replicon particles. J Infect Dis 184 (2001) 1613-1616
259. Chen M., Hu K.-F., Rozell B., Orvell C., Morein B., and Liljestrom P. Vaccination with recombinant alphavirus or recombinant immunostimulating complex antigen against respiratory sincytial virus. J Immunol 169 (2002) 3208-3216
260. MacDonald G.H., and Johnston R.E. Role of dendritic cell targeting in Venezuelan equine encephalitis pathogenesis. J Virol 74 (2000) 914-922
261. Gardner J.P., Frolov I., and Perri Sea. Infection of human dendritic cells by a Sindbis virus replicon vector is determined by a single aminoacid substitution in the E2 glycoprotein. J Virol 74 (2000) 11849-11857
262. Hariharan M.J., Driver D.A., Townsend K., Brumm D., Polo J.M., Belli B.A., et al. DNA immunization against herpes simplex virus: enhanced efficacy using a Sindbis virus-based vector. J Virol 72 (1998) 950-958
263. Berglund P., Smerdou C., Fleeton M.N., Tubulekas I., and Liljestrom P. Enhancing immune responses using suicidal DNA vaccines. Nat Biotechnol 16 (1998) 562-565
264. Dory D., Torche A.M., Beven V., Blanchard P., Loizel C., Cariolet R., et al. Effective protection of pigs against lethal Pseudorabies virus infection after a single injection of low-dose Sindbis-derived plasmids encoding PrV gB, gC and gD glycoproteins. Vaccine 23 May (26) (2005) 3483-3491
265. Leitner W.W., Ying H., Driver D.A., Dubensky T.W., and Restifo N.P. Enhancement of tumor-specific immune response with plasmid DNA replicon vectors. Cancer Res 60 January (1) (2000) 51-55
266. Lai M.M.C., and Cavanagh D. The molecular biology of coronaviruses. Adv Virus Res 48 (1997) 1-100
267. Enjuanes L., Sola I., Alonso S., Escors D., and Zúñiga S. Coronavirus reverse genetics and development of vectors for gene expression. Curr Top Microbiol Immunol 287 (2005) 161-197
268. Kuo L., Godeke G.-J., Raamsman M.J.B., Masters P.S., and Rottier P.J.M. Retargeting of coronavirus by substitution of the spike glycoprotein ectodomain: crossing the host cell species barrier. J Virol 74 (2000) 1393-1406
269. Masters P.S. Reverse genetics of the largest RNA viruses. Adv Virus Res 53 (1999) 245-264
270. Almazán F., González J.M., Pénzes Z., Izeta A., Calvo E., Plana-Durán J., et al. Engineering the largest RNA virus genome as an infectious bacterial artificial chromosome. Proc Natl Acad Sci U S A 97 (2000) 5516-5521
271. Yount B., Curtis K.M., and Baric R.S. Strategy for systematic assembly of large RNA and DNA genomes: the transmissible gastroenteritis virus model. J Virol 74 (2000) 10600-10611
272. Thiel V., Herold J., Schelle B., and Siddell S. Infectious RNA transcribed in vitro from a cDNA copy of the human coronavirus genome cloned in vaccinia virus. J Gen Virol 82 (2001) 1273-1281
273. St-Jean J.R., Desforges M., Almazan F., Jacomy H., Enjuanes L., and Talbot P.J. Recovery of a neurovirulent human coronavirus OC43 from an infectious cDNA clone. J Virol 80 (2006) 3670-3674
274. Yount B., Curtis K.M., Fritz E.A., Hensley L.E., Jahrling P.B., Prentice E., et al. Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci U S A 100 (2003) 12995-13000
275. Yount B., Denison M.R., Weiss S.R., and Baric R.S. Systematic assembly of a full-length infectious cDNA of mouse hepatitis virus strain A59. J Virol 76 (2002) 11065-11078
276. Casais R., Thiel V., Siddell S.G., Cavanagh D., and Britton P. Reverse genetics system for the avian coronavirus infectious bronchitis virus. J Virol 75 (2001) 12359-12369
277. Sola I., Alonso S., Zúñiga S., Balach M., Plana-Durán J., and Enjuanes L. Engineering transmissible gastroenteritis virus genome as an expression vector inducing latogenic immunity. J Virol 77 (2003) 4357-4369
278. Agapov E.V., Frolov I., Lindenbach B.D., Pragai B.M., Schlesinger S., and Rice C.M. Noncytopathic Sindbis virus RNA vectors for heterologous gene expression. Proc Natl Acad Sci U S A 95 (1998) 12989-12994
279. Curtis K.M., Yount B., and Baric R.S. Heterologous gene expression from transmissible gastroenteritis virus replicon particles. J Virol 76 (2002) 1422-1434
280. Youn S., Leibowitz J.L., and Collisson E.W. In vitro assembled, recombinant infectious bronchitis viruses demonstrate that the 5a open reading frame is not essential for replication. Virology 332 (2005) 206-215
281. Almazan F., Galan C., and Enjuanes L. The nucleoprotein is required for efficient coronavirus genome replication. J Virol 78 (2004) 12683-12688
282. Thiel V., Herold J., Schelle B., and Siddell S.G. Viral replicase gene products suffice for coronavirus discontinuous transcription. J Virol 75 (2001) 6676-6681
283. Schelle B., Karl N., Ludewig B., Siddell S.G., and Thiel V. Selective replication of coronavirus genomes that express nucleocapsid protein. J Virol 79 (2005) 6620-6630
284. Thiel V., Karl N., Schelle B., Disterer P., Klagge I., and Siddell S.G. Multigene RNA vector based on coronavirus transcription. J Virol 77 (2003) 9790-9798
285. Ortego J., Escors D., Laude H., and Enjuanes L. Generation of a replication-competent, propagation-deficient virus vector based on the transmissible gastroenteritis coronavirus genome. J Virol 76 (2002) 11518-11529
286. Ortego J., Ceriani J.E., Patiño C., Plana J., and Enjuanes L. Absence of E protein arrests transmissible gastroenteritis coronavirus maturation in the secretory pathway. Virology 368 (2007) 296-308
287. Dyall J., Latouche J.B., and Schnell Sea. Lentivirus-transduced human monocyte-derived dendritic cells efficiently stimulate antigen-specific cytotoxic T lymphocytes. Blood 97 (2001) 114-121
288. Rohrlich P.S., Cardinaud S., and Lule J. Use of a lentiviral vector encoding a HCMV-chimeric IE1-pp65 protein for epitope identification in HLA-transgenic mice and for ex-vivo stimulation and expansion of CD8+ cytotoxic T-cells from human peripheral blood cells. Hum Immunol 65 (2004) 514-522
289. Zarel S., Abraham S., and Arrighi J.F. Lentiviral transduction of dendritic cells confers protective antiviral immunity in vivo. J Virol 78 (2004) 7843-7845
290. Iglesias M., Frenkiel M., Mollier K., Souque P., Despres P., and Charneau P. A single immunization with a minute dose of a lentiviral vector-based vaccine is highly effective at eliciting protective humoral immunity against West Nile virus. J Gene Med 8 (2006) 265-274
291. Schwantes A., Truyen U., Weikel J., Weiss C., and Löchelt M. Application of chimeric feline foamy virus-based retroviral vectors for the induction of antiviral immunity in cats. J Virol 77 14 (2003) 7830-7842
292. Metharom P., Takyar S., Xia X.Q., Ellem K.A.O., Wilcox G.E., and Wei M.Q. Development of disabled, replication-defective gene transfer vectors from the Jembrana disease virus, a new infectious agent of cattle. Vet Microbiol 80 (2001) 9-22
293. Arroyo J., Miller C., Catalan J., Myers G.A., Ratterree M.S., and Trent D.W.E.A. Chimeri-vax-West Nile virus live attenuated vaccine: preclinical evaluation of safety, immunogenicity and efficacy. J Virol 78 (2004) 12497-12507
294. Wehrle F., Renzullo S., Faust A., Beer M., Kaden V., and Hofmann M.A. Chimeric pestiviruses: candidates for live-attenuated classical swine fever vaccines. J Gen Virol 88 (2007) 2247-2258
295. Yilma T., Hsu D., Jones L., Owens S., Grubman M., Mebus C., et al. Protection of cattle against rinderpest with vaccinia virus recombinants expressing the HA or F gene. Science 242 November (4881) (1988) 1058-1061
296. Giavedoni L., Jones L., Mebus C., and Yilma T. A vaccinia virus double recombinant expressing the F and H genes of rinderpest virus protects cattle against rinderpest and causes no pock lesions. Proc Natl Acad Sci U S A 88 September (18) (1991) 8011-8015
297. Ohishi K., Inui K., Barrett T., and Yamanouchi K. Long-term protective immunity to rinderpest in cattle following a single vaccination with a recombinant vaccinia virus expressing the virus haemagglutinin protein. J Gen Virol 81 June (Pt 6) (2000) 1439-1446
298. Verardi P.H., Aziz F.H., Ahmad S., Jones L.A., Beyene B., Ngotho R.N., et al. Long-term sterilizing immunity to rinderpest in cattle vaccinated with a recombinant vaccinia virus expressing high levels of the fusion and hemagglutinin glycoproteins. J Virol 76 January (2) (2002) 484-491
299. Taylor G., Thomas L.H., Furze J.M., Cook R.S., Wyld S.G., Lerch R., et al. Recombinant vaccinia viruses expressing the F, G or N, but not the M2, protein of bovine respiratory syncytial virus (BRSV) induce resistance to BRSV challenge in the calf and protect against the development of pneumonic lesions. J Gen Virol 78 December (Pt 12) (1997) 3195-3206
300. Hertig C., Pye A.D., Hyatt A.D., Davis S.S., McWilliam S.M., Heine H.G., et al. Vaccinia virus-expressed bovine ephemeral fever virus G but not G(NS) glycoprotein induces neutralizing antibodies and protects against experimental infection. J Gen Virol 77 April (Pt 4) (1996) 631-640
301. Honda Y., Waithaka M., Taracha E.L., Duchateau L., Musoke A.J., and McKeever D.J. Delivery of the Theileria parva p67 antigen to cattle using recombinant vaccinia virus: IL-2 enhances protection. Vaccine 16 August (13) (1998) 1276-1282
302. Lobato Z.I., Coupar B.E., Gray C.P., Lunt R., and Andrew M.E. Antibody responses and protective immunity to recombinant vaccinia virus-expressed bluetongue virus antigens. Vet Immunol Immunopathol 59 November (3-4) (1997) 293-309
303. Portetelle D., Limbach K., Burny A., Mammerickx M., Desmettre P., Riviere M., et al. Recombinant vaccinia virus expression of the bovine leukaemia virus envelope gene and protection of immunized sheep against infection. Vaccine 9 March (3) (1991) 194-200
304. Gatei M.H., Naif H.M., Kumar S., Boyle D.B., Daniel R.C., Good M.F., et al. Protection of sheep against bovine leukemia virus (BLV) infection by vaccination with recombinant vaccinia viruses expressing BLV envelope glycoproteins: correlation of protection with CD4 T-cell response to gp51 peptide 51-70. J Virol 67 April (4) (1993) 1803-1810
305. Cheevers W.P., Hotzel I., Beyer J.C., and Kumpula-McWhirter N. Immune response to caprine arthritis-encephalitis virus surface protein induced by coimmunization with recombinant vaccinia viruses expressing the caprine arthritis-encephalitis virus envelope gene and caprine interleukin-12. Vaccine 18 May (23) (2000) 2494-2503
306. Rumenapf T., Stark R., Meyers G., and Thiel H.J. Structural proteins of hog cholera virus expressed by vaccinia virus: further characterization and induction of protective immunity. J Virol 65 February (2) (1991) 589-597
307. Konig M., Lengsfeld T., Pauly T., Stark R., and Thiel H.J. Classical swine fever virus: independent induction of protective immunity by two structural glycoproteins. J Virol 69 October (10) (1995) 6479-6486
308. Chambers T.M., Kawaoka Y., and Webster R.G. Protection of chickens from lethal influenza infection by vaccinia-expressed hemagglutinin. Virology 167 December (2) (1988) 414-421
309. Antonis A.F., van der Most R.G., Suezer Y., Stockhofe-Zurwieden N., Daus F., Sutter G., et al. Vaccination with recombinant modified vaccinia virus Ankara expressing bovine respiratory syncytial virus (bRSV) proteins protects calves against RSV challenge. Vaccine 25 June (25) (2007) 4818-4827
310. Breathnach C.C., Clark H.J., Clark R.C., Olsen C.W., Townsend H.G., and Lunn D.P. Immunization with recombinant modified vaccinia Ankara (rMVA) constructs encoding the HA or NP gene protects ponies from equine influenza virus challenge. Vaccine 24 February (8) (2006) 1180-1190
311. Vordermeier H.M., Rhodes S.G., Dean G., Goonetilleke N., Huygen K., Hill A.V., et al. Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-Guerin. Immunology 112 July (3) (2004) 461-470
312. Konishi E., Pincus S., Paoletti E., Laegreid W.W., Shope R.E., and Mason P.W. A highly attenuated host range-restricted vaccinia virus strain, NYVAC, encoding the prM, E, and NS1 genes of Japanese encephalitis virus prevents JEV viremia in swine. Virology 190 September (1) (1992) 454-458
313. Brockmeier S.L., Lager K.M., Tartaglia J., Riviere M., Paoletti E., and Mengeling W.L. Vaccination of pigs against pseudorabies with highly attenuated vaccinia (NYVAC) recombinant viruses. Vet Microbiol 38 December (1-2) (1993) 41-58
314. Brockmeier S.L., Lager K.M., and Mengeling W.L. Vaccination with recombinant vaccinia virus vaccines expressing glycoprotein genes of pseudorabies virus in the presence of maternal immunity. Vet Microbiol 58 November (2-4) (1997) 93-103
315. Weingartl H.M., Berhane Y., Caswell J.L., Loosmore S., Audonnet J.C., Roth J.A., et al. Recombinant nipah virus vaccines protect pigs against challenge. J Virol 80 August (16) (2006) 7929-7938
316. Tartaglia J., Jarrett O., Neil J.C., Desmettre P., and Paoletti E. Protection of cats against feline leukemia virus by vaccination with a canarypox virus recombinant, ALVAC-FL. J Virol 67 April (4) (1993) 2370-2375
317. Poulet H., Brunet S., Boularand C., Guiot A.L., Leroy V., Tartaglia J., et al. Efficacy of a canarypox virus-vectored vaccine against feline leukaemia. Vet Rec 153 August (5) (2003) 141-145
318. Siger L., Bowen R., Karaca K., Murray M., Jagannatha S., Echols B., et al. Evaluation of the efficacy provided by a recombinant canarypox-vectored equine West Nile Virus vaccine against an experimental West Nile Virus intrathecal challenge in horses. Vet Ther 7 Fall (3) (2006) 249-256
319. Siger L., Bowen R.A., Karaca K., Murray M.J., Gordy P.W., Loosmore S.M., et al. Assessment of the efficacy of a single dose of a recombinant vaccine against West Nile virus in response to natural challenge with West Nile virus-infected mosquitoes in horses. Am J Vet Res 65 November (11) (2004) 1459-1462
320. Minke J.M., Siger L., Karaca K., Austgen L., Gordy P., Bowen R., et al. Recombinant canarypoxvirus vaccine carrying the prM/E genes of West Nile virus protects horses against a West Nile virus-mosquito challenge. Arch Virol Suppl 18 (2004) 221-230
321. Minke J.M., Toulemonde C.E., Dinic S., Cozette V., Cullinane A., and Audonnet J.C. Effective priming of foals born to immune dams against influenza by a canarypox-vectored recombinant influenza H3N8 vaccine. J Comp Pathol 137 July (Suppl. 1) (2007) S76-S80
322. McCabe V.J., Tarpey I., and Spibey N. Vaccination of cats with an attenuated recombinant myxoma virus expressing feline calicivirus capsid protein. Vaccine 20 June (19-20) (2002) 2454-2462
323. Torres J.M., Ramirez M.A., Morales M., Barcena J., Vazquez B., Espuna E., et al. Safety evaluation of a recombinant myxoma-RHDV virus inducing horizontal transmissible protection against myxomatosis and rabbit haemorrhagic disease. Vaccine 19 September (2-3) (2000) 174-182
324. Romero C.H., Barrett T., Evans S.A., Kitching R.P., Gershon P.D., Bostock C., et al. Single capripoxvirus recombinant vaccine for the protection of cattle against rinderpest and lumpy skin disease. Vaccine 11 7 (1993) 737-742
325. Romero C.H., Barrett T., Kitching R.P., Carn V.M., and Black D.N. Protection of cattle against rinderpest and lumpy skin disease with a recombinant capripoxvirus expressing the fusion protein gene of rinderpest virus. Vet Rec 135 August (7) (1994) 152-154
326. Ngichabe C.K., Wamwayi H.M., Barrett T., Ndungu E.K., Black D.N., and Bostock C.J. Trial of a capripoxvirus-rinderpest recombinant vaccine in African cattle. Epidemiol Infect 118 February (1) (1997) 63-70
327. Taylor J., Weinberg R., Kawaoka Y., Webster R.G., and Paoletti E. Protective immunity against avian influenza induced by a fowlpox virus recombinant. Vaccine 6 December (6) (1988) 504-508
328. Swayne D.E., Beck J.R., and Mickle T.R. Efficacy of recombinant fowl poxvirus vaccine in protecting chickens against a highly pathogenic Mexican-origin H5N2 avian influenza virus. Avian Dis 41 October-December (4) (1997) 910-922
329. Qiao C.L., Yu K.Z., Jiang Y.P., Jia Y.Q., Tian G.B., Liu M., et al. Protection of chickens against highly lethal H5N1 and H7N1 avian influenza viruses with a recombinant fowlpox virus co-expressing H5 haemagglutinin and N1 neuraminidase genes. Avian Pathol 32 February (1) (2003) 25-32
330. Bublot M., Pritchard N., Cruz J.S., Mickle T.R., Selleck P., and Swayne D.E. Efficacy of a fowlpox-vectored avian influenza H5 vaccine against Asian H5N1 highly pathogenic avian influenza virus challenge. Avian Dis 51 March (1 Suppl.) (2007) 498-500
331. Ogawa R., Yanagida N., Saeki S., Saito S., Ohkawa S., Gotoh H., et al. Recombinant fowlpox viruses inducing protective immunity against Newcastle disease and fowlpox viruses. Vaccine 8 October (5) (1990) 486-490
332. Boursnell M.E., Green P.F., Samson A.C., Campbell J.I., Deuter A., Peters R.W., et al. A recombinant fowlpox virus expressing the hemagglutinin-neuraminidase gene of Newcastle disease virus (NDV) protects chickens against challenge by NDV. Virology 178 September (1) (1990) 297-300
333. Taylor J., Christensen L., Gettig R., Goebel J., Bouquet J.F., Mickle T.R., et al. Efficacy of a recombinant fowl pox-based Newcastle disease virus vaccine candidate against velogenic and respiratory challenge. Avian Dis 40 January-March (1) (1996) 173-180
334. Karaca K., Sharma J.M., Winslow B.J., Junker D.E., Reddy S., Cochran M., et al. Recombinant fowlpox viruses coexpressing chicken type I IFN and Newcastle disease virus HN and F genes: influence of IFN on protective efficacy and humoral responses of chickens following in ovo or post-hatch administration of recombinant viruses. Vaccine 16 October (16) (1998) 1496-1503
335. Heine H.G., Foord A.J., Young P.L., Hooper P.T., Lehrbach P.R., and Boyle D.B. Recombinant fowlpox virus vaccines against Australian virulent Marek's disease virus: gene sequence analysis and comparison of vaccine efficacy in specific pathogen free and production chickens. Virus Res 50 July (1) (1997) 23-33
336. Calvert J.G., Nazerian K., Witter R.L., and Yanagida N. Fowlpox virus recombinants expressing the envelope glycoprotein of an avian reticuloendotheliosis retrovirus induce neutralizing antibodies and reduce viremia in chickens. J Virol 67 June (6) (1993) 3069-3076
337. Heine H.G., and Boyle D.B. Infectious bursal disease virus structural protein VP2 expressed by a fowlpox virus recombinant confers protection against disease in chickens. Arch Virol 131 3-4 (1993) 277-292
338. Qingzhong Y., Barrett T., Brown T.D., Cook J.K., Green P., Skinner M.A., et al. Protection against turkey rhinotracheitis pneumovirus (TRTV) induced by a fowlpox virus recombinant expressing the TRTV fusion glycoprotein (F). Vaccine 12 May (6) (1994) 569-573
339. Fischer T., Planz O., Stitz L., and Rziha H.J. Novel recombinant parapoxvirus vectors induce protective humoral and cellular immunity against lethal herpesvirus challenge in mice. J Virol 77 (2003) 9312-9323
340. Henkel M., Planz O., Fischer T., Stitz L., and Rziha H.J. Prevention of virus persistence and protection against immunopathology after Borna disease virus infection of the brain by a novel Orf virus recombinant. J Virol 79 (2005) 314-325
341. Dory D., Fischer T., Béven V., Cariolet R., Rziha H.J., and Jestin A. Prime-boost immunization using DNA vaccine and recombinant Orf virus protects pigs against Pseudorabies virus (Herpes suid 1). Vaccine 24 (2006) 6256-6263
342. Veits J., Lüschow D., Kindermann K., Werner O., Teifke J., Mettenleiter T.C., et al. Deletion of the non-essential ULO gene of infectious laryngotracheitis (ILT) virus leads to attenuation in chickens, and UL0 mutants expressing influenza virus haemagglutinin (H7) protect against ILT and fowl plaque. J Gen Virol 84 (2003) 3343-3352
343. Peeters B., Bienkowska-Szewczyk K., Hulst M., Gielens A., and Kimman T. Biologically safe, no-transmissible pseudorabies virus vector vaccine protects pigs against both Aujeszky's disease and classical swine fever. J Gen Virol 78 (1997) 3311-3315